MA50534A - Variant d'anticorps et isoforme à activité biologique réduite - Google Patents
Variant d'anticorps et isoforme à activité biologique réduiteInfo
- Publication number
- MA50534A MA50534A MA050534A MA50534A MA50534A MA 50534 A MA50534 A MA 50534A MA 050534 A MA050534 A MA 050534A MA 50534 A MA50534 A MA 50534A MA 50534 A MA50534 A MA 50534A
- Authority
- MA
- Morocco
- Prior art keywords
- isoform
- biological activity
- antibody variant
- reduced biological
- reduced
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017212179 | 2017-11-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50534A true MA50534A (fr) | 2020-09-09 |
Family
ID=66331990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050534A MA50534A (fr) | 2017-11-01 | 2018-10-31 | Variant d'anticorps et isoforme à activité biologique réduite |
Country Status (19)
Country | Link |
---|---|
US (1) | US20200283544A1 (fr) |
EP (1) | EP3705496A4 (fr) |
JP (2) | JPWO2019088143A1 (fr) |
KR (1) | KR20200074209A (fr) |
CN (1) | CN111479829A (fr) |
AR (1) | AR113816A1 (fr) |
AU (1) | AU2018361430A1 (fr) |
BR (1) | BR112020008393A2 (fr) |
CA (1) | CA3079053A1 (fr) |
CL (1) | CL2020001113A1 (fr) |
CR (1) | CR20200229A (fr) |
IL (1) | IL274265A (fr) |
MA (1) | MA50534A (fr) |
MX (1) | MX2020003472A (fr) |
PE (1) | PE20210553A1 (fr) |
SA (1) | SA520411871B1 (fr) |
SG (1) | SG11202003833TA (fr) |
TW (1) | TW201930352A (fr) |
WO (1) | WO2019088143A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2202245T3 (pl) | 2007-09-26 | 2017-02-28 | Chugai Seiyaku Kabushiki Kaisha | Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr |
AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體 |
EP3398965A4 (fr) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Procédé pour favoriser l'efficacité de purification d'un polypeptide contenant une région fc |
CN109661241A (zh) | 2016-09-06 | 2019-04-19 | 中外制药株式会社 | 使用识别凝血因子ix和/或活化凝血因子ix以及凝血因子x和/或活化凝血因子x的双特异性抗体的方法 |
AU2018361430A1 (en) | 2017-11-01 | 2020-06-11 | Chugai Seiyaku Kabushiki Kaisha | Antibody variant and isoform with lowered biological activity |
WO2023120561A1 (fr) * | 2021-12-22 | 2023-06-29 | 中外製薬株式会社 | Variant d'anticorps à activité biologique réduite |
CN114544839A (zh) * | 2022-01-20 | 2022-05-27 | 未名生物医药有限公司 | 一种抗人神经生长因子抗体的电荷变异体检测方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5641870A (en) * | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
WO2005035754A1 (fr) | 2003-10-14 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | Anticorps a double specificite de substitution de proteine fonctionnelle |
AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
EP1876236B9 (fr) | 2005-04-08 | 2015-02-25 | Chugai Seiyaku Kabushiki Kaisha | Anticorps de substitution de la fonction du facteur viii de coagulation sanguine |
EP4218801A3 (fr) * | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Procédé de modification d'anticorps pour purifier un anticorps bispécifique |
CN101460622A (zh) * | 2006-03-31 | 2009-06-17 | 中外制药株式会社 | 用于纯化双特异性抗体的抗体修饰方法 |
BRPI0716762A2 (pt) * | 2006-09-13 | 2013-09-24 | Abbott Lab | melhorias da cultura celular |
PL2202245T3 (pl) * | 2007-09-26 | 2017-02-28 | Chugai Seiyaku Kabushiki Kaisha | Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr |
MY166429A (en) * | 2010-11-17 | 2018-06-26 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
EP3147355B1 (fr) * | 2010-12-27 | 2020-07-22 | Kyowa Kirin Co., Ltd. | Procédé de préparation d'une solution aqueuse contenant un milieu de culture et un agent chélatant |
US20140371427A1 (en) | 2011-12-07 | 2014-12-18 | Amgen Inc. | IgG2 DISULFIDE ISOFORM SEPARATION |
GB201203051D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
AU2016245887B2 (en) * | 2015-04-10 | 2021-09-23 | Adimab, Llc. | Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species |
EP3395835B1 (fr) * | 2015-12-25 | 2021-02-03 | Chugai Seiyaku Kabushiki Kaisha | Anticorps présentant une activité accrue et son procédé de modification |
AU2018361430A1 (en) | 2017-11-01 | 2020-06-11 | Chugai Seiyaku Kabushiki Kaisha | Antibody variant and isoform with lowered biological activity |
-
2018
- 2018-10-31 AU AU2018361430A patent/AU2018361430A1/en active Pending
- 2018-10-31 CR CR20200229A patent/CR20200229A/es unknown
- 2018-10-31 CA CA3079053A patent/CA3079053A1/fr active Pending
- 2018-10-31 KR KR1020207015464A patent/KR20200074209A/ko not_active Application Discontinuation
- 2018-10-31 SG SG11202003833TA patent/SG11202003833TA/en unknown
- 2018-10-31 MA MA050534A patent/MA50534A/fr unknown
- 2018-10-31 PE PE2020000451A patent/PE20210553A1/es unknown
- 2018-10-31 BR BR112020008393-3A patent/BR112020008393A2/pt unknown
- 2018-10-31 CN CN201880080142.XA patent/CN111479829A/zh active Pending
- 2018-10-31 WO PCT/JP2018/040436 patent/WO2019088143A1/fr unknown
- 2018-10-31 EP EP18873627.6A patent/EP3705496A4/fr active Pending
- 2018-10-31 TW TW107138518A patent/TW201930352A/zh unknown
- 2018-10-31 MX MX2020003472A patent/MX2020003472A/es unknown
- 2018-10-31 US US16/758,128 patent/US20200283544A1/en active Pending
- 2018-10-31 AR ARP180103169A patent/AR113816A1/es unknown
- 2018-10-31 JP JP2019550437A patent/JPWO2019088143A1/ja not_active Withdrawn
-
2020
- 2020-04-27 IL IL274265A patent/IL274265A/en unknown
- 2020-04-27 CL CL2020001113A patent/CL2020001113A1/es unknown
- 2020-04-29 SA SA520411871A patent/SA520411871B1/ar unknown
-
2023
- 2023-11-29 JP JP2023202127A patent/JP2024037761A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3079053A1 (fr) | 2019-05-09 |
RU2020117440A3 (fr) | 2022-04-01 |
CR20200229A (es) | 2020-07-12 |
WO2019088143A1 (fr) | 2019-05-09 |
AR113816A1 (es) | 2020-06-17 |
PE20210553A1 (es) | 2021-03-17 |
CN111479829A (zh) | 2020-07-31 |
CL2020001113A1 (es) | 2020-11-20 |
RU2020117440A (ru) | 2021-12-01 |
EP3705496A1 (fr) | 2020-09-09 |
AU2018361430A1 (en) | 2020-06-11 |
TW201930352A (zh) | 2019-08-01 |
IL274265A (en) | 2020-06-30 |
EP3705496A4 (fr) | 2021-12-08 |
SA520411871B1 (ar) | 2023-12-19 |
MX2020003472A (es) | 2020-08-03 |
JP2024037761A (ja) | 2024-03-19 |
BR112020008393A2 (pt) | 2020-11-03 |
KR20200074209A (ko) | 2020-06-24 |
SG11202003833TA (en) | 2020-05-28 |
US20200283544A1 (en) | 2020-09-10 |
JPWO2019088143A1 (ja) | 2020-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50534A (fr) | Variant d'anticorps et isoforme à activité biologique réduite | |
MA46820A (fr) | Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques | |
MA44776A (fr) | Anticorps anti-vista humain et leur utilisation | |
MA53434A (fr) | Anticorps anti-tigit | |
MA52884A (fr) | Anticorps anti-il-11 | |
MA54615A (fr) | Anticorps monoclonal contre le récepteur alpha de l'interleukine-4 humaine et son utilisation | |
MA49512A (fr) | Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation | |
MA51747A (fr) | Formulation d'anticorps pharmaceutique à ph faible | |
UA42295S (uk) | Комп'ютер | |
MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
MA51066A (fr) | Inhibiteurs d'intégrine | |
MA45941A (fr) | Anticorps de membres de la superfamille anti-tnfr modifiés par fc ayant une activité agoniste améliorée et leurs procédés d'utilisation | |
MA55033A (fr) | Formulation d'anticorps thérapeutique | |
MA52014A (fr) | Anticorps anti-klk5 et méthodes d'utilisation | |
MA53122A (fr) | Variants d'anticorps cd38 et leurs utilisations | |
UA42369S (uk) | Комп'ютер | |
MA55818A (fr) | Anticorps et immunoconjugués de fr-alpha biparatopique | |
MA52190A (fr) | Anticorps anti-trem-1 et utilisations associées | |
MA55305A (fr) | Anticorps bispécifiques anti-v béta 17/anti-cd123 | |
MA51147A (fr) | Associations d'anticorps anti-c5 et utilisations associées | |
MA43049A (fr) | Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1) | |
MA56466A (fr) | Anticorps anti-epha4 | |
MA55600A (fr) | Anticorps anti-ige | |
MA45167A (fr) | Peptidomimétique en épingle à cheveux bêta présentant une activité d'inhibition de l'élastase et formes pharmaceutiques aérosols correspondantes | |
MA54089A (fr) | Anticorps anti-pd-1 humain et procédés d'utilisation associés |